Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(8):577-579; doi:10.1093/jnci/95.8.577
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schultz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schultz, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 8, 577-579, April 16, 2003
© 2003 Oxford University Press

NEWS

Apparent Adverse Drug Reactions Prompt Concern About Iressa

James Schultz

The first 10% of the full text of this article appears below.

Effective last-resort cancer medications are few and far between. When preliminary evidence indicated that the medication Iressa—also known as ZD1839 or gefitinib—might be a substantial advance in the treatment of late-stage lung cancers, at least for some patients, pharmaceutical manufacturer AstraZeneca pushed for accelerated approval from the U.S. Food and Drug Administration. Last September, during an Oncologic Drugs Advisory Committee (ODAC) meeting, panelists agreed, voting 11-3 to recommend that Iressa be approved by the FDA for use by patients who had not responded to at least two chemotherapy agents, and thus would have no further treatment option (see News, Nov. 6, Vol. 94, . . . [Full Text of this Article]

‘Put Into a Context’

Tumor Response

More Studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
P M Harari
Epidermal growth factor receptor inhibition strategies in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708.
[Abstract] [Full Text] [PDF]